SPHK2 and metabolic dysfunction-associated steatotic liver disease: Our results collectively indicate that SphK2 deficiency reduces HCC risk in fatty livers at both systemic and cellular levels, providing in vivo experimental evidence for clinical trials of SphK2 inhibitors as systemic therapies against NAFLD-HCC.